Seeking Alpha

Investorideas.com's  Instablog

Investorideas.com
Send Message
www.InvestorIdeas.com is a meeting place for investors and public companies in leading sectors. Find investing ideas, news and research for biotech stocks, tech and mobile stocks, mining stocks, oil and gas, water stocks, renewable energy, beverage stocks, defense stocks, nanotech and more on... More
My company:
Investor Ideas
My blog:
Investor Ideas Newswire
View Investorideas.com's Instablogs on:
  • Biotech News Alert: GenSpera's (OTCQB:GNSZ) CEO Shares Insight On Unique Properties And Targeting Of Lead Drug G-202, Based On The Thapsigargin Toxin

    Biotech News Alert: GenSpera's (OTCQB:GNSZ) CEO Shares Insight on Unique Properties and Targeting of Lead Drug G-202, Based on the Thapsigargin Toxin

    POINT ROBERTS, Wash. and NEW YORK - August 5, 2014 (Investorideas.com Biotech Newswire) Investorideas.com, a global news source covering leading sectors including biotech, issues an exclusive Q&A interview with Dr. Craig Dionne, PhD, GenSpera's (OTCQB:GNSZ) CEO. Dr. Dionne discusses the company's lead drug G-202 and how they have taken a powerful toxin named thapsigargin to selectively target and kill cancer cells.

    He also shares insight into the key points that make them different from competitive drugs available on the market for certain cancers.

    Q: Investorideas.com

    Craig for readers unfamiliar with your company, can you explain the basis for your lead drug G-202 and how it works?

    A: Dr. Craig Dionne, PhD, GenSpera CEO

    There are really two important characteristics that distinguish G-202 from other chemotherapeutic agents. First, the active ingredient in G-202 is much more potent than other anti-cancer drugs and kills in a way that does not allow tumor cells to escape being killed. Second, G-202 is designed as a pro-drug that is expected to release the active ingredient only at the tumor itself, thereby maximizing anti-tumor effect and minimizing side effects.

    Q: Investorideas.com

    And in particular can you explain how the targeting kills the tumor only and give us insight into the safety profile?

    A: Dr. Craig Dionne, PhD, GenSpera CEO

    G-202 is designed so that it may be activated by the enzyme PSMA that is found at high levels in the blood vessels of almost all types of solid tumors, on the surface of prostate cancer cells and at very few other places in the body. G-202 circulates safely in the bloodstream until it comes in contact with PSMA which releases the active ingredient, 12ADT, which then falls into the tumor and does not come back into the bloodstream to cause toxicity elsewhere in the body. G-202 is administered to patients as an IV infusion over about one hour on three consecutive days - this dosing regimen is repeated at 28-day intervals. In keeping with the way G-202 is designed, patients experience very minor and easily managed side effects of nausea on days of drug administration, fatigue for a few days and a minor temporary rash. Importantly, G-202 has no effect on the bone marrow so there is no immunosuppression or anemia. This lack of significant side effects implies that we should be able to combine G-202 with other anti-cancer agents to maximize killing of the cancerous tumors in patients.

    Q: Investorideas.com

    The company just recently released G-202 hepatocellular carcinoma ("HCC", which is liver cancer) clinical trial data at two prestigious industry conferences. Can you summarize the results released and also how has the data been embraced by your industry peers?

    A: Dr. Craig Dionne, PhD, GenSpera CEO

    We are testing G-202 in hepatocellular carcinoma patients who have had tumors regrow after being treated with sorafenib, which is the only approved drug for this patient population. Those patients who fail sorafenib and subsequently enter clinical trials for other experimental drugs usually have documented tumor regrowth at only two months. In our G-202 study we found that 80% of patients exhibited disease stabilization (no tumor regrowth) at 2 months. We also demonstrated that a significant proportion of patients, approximately 30%, have tumors stop growing for at least six months with one patient still receiving drug two years after coming into the trial. We then used a sophisticated imaging technique that visualizes blood flow through the tumor in a patient before starting our drug and again after two cycles of treatment to show that G-202 dramatically diminishes blood flow to the tumor, presumably by destroying the tumor blood vessels. The consensus among our industry peers is that G-202 is an active drug that does exactly what it is designed to do and at doses that are very well-tolerated by the patients.

    Q: Investorideas.com

    Can you talk about the multiple cancers that G-202 can potentially treat and the kind of market opportunity each represents?

    A: Dr. Craig Dionne, PhD, GenSpera CEO

    We expect G-202 to be useful in a wide range of malignant tumor types, which covers a multi-billion dollar industry opportunity for GenSpera. There are approximately 240,000 new cases of prostate cancer diagnosed in the US each year. The market for prostate cancer drugs is expected to reach $6.7 billion by 2020. Hepatocellular carcinoma is the third largest cancer killer worldwide with an expected market size of $1.5 billion by 2019. Glioblastoma is a smaller market but sales of the approved drug Avastin in those patients is expected to reach $460 million by 2017. However we view glioblastoma as a proof of concept for treating brain tumors; if successful, we expect that G-202 could be used to treat lung and breast cancers that metastasize to the brain, which is a 10-fold larger market than glioblastoma alone.

    Q: Investorideas.com

    How would you describe the G-202 proof of concept to-date in terms that an average reader could understand, outside of the scientific community?

    A: Dr. Craig Dionne, PhD, GenSpera CEO

    G-202 is designed to be activated only within the blood vessels of tumors and to kill those blood vessels directly, thus starving the tumors to death. We used a very sophisticated imaging technique to demonstrate that G-202 treatment nearly obliterated tumor blood flow in a liver cancer patient after only two cycles of treatment. These results bode well for our prostate cancer and glioblastoma (brain cancer) clinical trials, which use exactly the same dosing regimen.

    Q: Investorideas.com

    Craig with your recent data on hepatocellular carcinoma (HCC or liver cancer) can you tell our readers how that compares with the current drug in the market?

    A: Dr. Craig Dionne, PhD, GenSpera CEO

    Sorafenib is the only approved drug for HCC and is used as the first line chemotherapy option. G-202 has only been tested in patients who have had tumor progression while on sorafenib and who are obviously patients of a later cancer stage. The fact that we are seeing positive signs of drug activity in this later stage patient population implies that we should see good activity when we test the drug in earlier stage patients. Certainly the G-202 side effect profile is much better than sorafenib, which causes nausea, neutropenia and hand-foot syndrome (blistering and peeling of palms of hands and soles of feet) in a significant proportion of patients.

    Q: Investorideas.com

    In closing can you summarize the next steps and estimated time-line forbringing G-202 to market?

    A: Dr. Craig Dionne, PhD, GenSpera CEO

    We continue to evaluate G-202 in the ongoing HCC, glioblastoma and prostate cancer trials, which are all considered early-stage single-arm studies. Our next trial with G-202 will likely be a small randomized Phase IIB study in combination with sorafenib or in combination with trans-arterial chemoembolization, both of which would be in much earlier stage cancer patients than those we have treated to date. Either study should be complete within two years at which time we could begin a Phase III registration study so we are likely to be six years away from commercialization in HCC. However, if our data is really positive in the glioblastoma trial, we likely could be approved a year or two earlier in that indication. In both cases as we report strong progress to the market, a strategic partnership with a major industry player is a possibility prior to receiving FDA approval.

    Watch the Corporate Video: http://youtu.be/jULjEul-mBk

    Read this release in full at http://www.investorideas.com/CO/GNSZ/news/2014/08051.asp

    Dr. Craig A. Dionne, PhD, President and CEO

    Craig A. Dionne, PhD, is one of Genspera's founders and has served on the board since November 2003. He has over 25 years of experience in the pharmaceutical industry, including direct experience in identifying promising oncology treatments and bringing them through the clinic. He served for several years as VP Discovery Research at Cephalon, Inc. (now Teva Pharmaceuticals), a biopharmaceutical company, where he was responsible for its oncology and neurobiology drug discovery and development programs. Dr. Dionne also served as Executive Vice President at the Prostate Cancer Research Foundation. In addition to extensive executive experience, Dr. Dionne's productive scientific career has led to six issued patents and co-authorship of many scientific papers. Dr. Dionne received his PhD from the University of Texas at Austin in 1984.

    About GenSpera (OTCQB:GNSZ):

    GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a pro-drug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, G-202, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. G-202 is therefore expected to have potential efficacy in a wide variety of tumor types.

    G-202 Phase II clinical trials are underway in hepatocellular carcinoma, glioblastoma and prostate cancer patients.

    For more information, please visit the company's website: http://www.genspera.com or follow on Twitter @GenSperaNews.

    InvestorIdeas.com is a global news source and research resource covering leading sectors including social media, tech, biotech, defense, water, mining and energy.

    Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

    Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

    Sign up for free news alerts at Investorideas.com:

    http://www.investorideas.com/Resources/Newsletter.asp

    Become an Investorideas.com Member and access our online stock directories listing thousands of publicly traded stocks in leading sectors: http://www.investorideas.com/membership

    Disclaimer/Disclosure: Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Genspera (OTCQB:GNSZ) has engaged Investor Ideas for PR and news publication effective June 18, 2014 (compensation of five thousand per month and average of eleven thousand five hundred 144 shares per month)

    BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

    Contact Investorideas.com: 800-665-0411

    Aug 05 1:56 PM | Link | Comment!
  • Proexport Colombia's Trade Commissioner Alvaro Concha Gives Insight Into Hotel Industry Growth And How Colombia Is Making Headlines Across The Board

    Colombia Sees 6.3% GDP Growth First Quarter; Second Only to China

    Colombia's World Cup Performance and 'Superstar in the Making' James Rodriguez add to a Changing Global Perception

    Investorideas.com WA, NEW YORK, Canada - July 22, 2014 - Investorideas.com, a global news source covering leading sectors including Latin America, releases an exclusive interview which provides insight into Colombia's growth, with a focus on the hotel industry.Proexport Colombia's Trade Commissioner Alvaro Concha discusses the changing global perception of the country and how Colombia continues to be a go-to destination for both business and tourists.

    Interview excerpt:

    Investorideas.com

    Good morning Alvaro, I imagine all of Colombia is both excited and a little sad about the World Cup performance. Making it to the quarter finals and the amazing goals by James Rodriguez definitely put Colombia on the map to viewers from around the world.

    It seems to be a great time for Colombia in a lot of ways. You just reported significant hotel industry growth and a rise in foreign visitor growth. Can you break down the numbers in foreign visitor growth in terms of countries of origin and where they visit most?

    Alvaro Concha

    Yes, thank you. We are more happy than sad. Colombia did a wonderful job. We now have another good reason to make the headlines. And if we keep stacking up positives, we will be recognized more and more for good reasons like this versus the bad reasons of the past.

    The Santos government has put a main objective by the end of 2014 of 4 million foreign visitors and we are pretty close, we are already at 3.7 million. Colombia is growing three times faster than the rest of the world in terms of tourism. The United States is the number one country visiting, also a few European countries, including Spain, is in the top group. Canada is always in the top ten; dropped out last year but always in the top group with over 44,000 visitors per year. We are targeting the Canadian eco-tourism market to attract more visitors as well. We are actively working with the tourism operators and the airline operators to promote what Colombia has to offer.

    Investorideas.com

    Also I see there was substantial increase in business visitors, indicating an ongoing interest and growth in doing business in Colombia. Can you give us some insight as to what sectors of business and what cities are being concentrated on?

    Alvaro Concha

    First thing to say is that Canadian companies are leading mining investment in Colombia. Also a lot of oil and gas companies, with one of the biggest company in oil and gas exploration being a Canadian based company. There is also a lot of other interest from pension funds, financial entities and infrastructure companies looking at Colombia. That is increasing every day, making Colombia a good destination for business. There are also at least two financial entities in Canada that are looking at opening operations in Colombia. Also in terms of the ICCA (http://www.iccaworld.com) global ranking, we keep improving and are now 28th, up from 32nd. This ranks the most attractive and secure countries for conventions. This makes Colombia an attractive destination to host conventions.

    Investorideas.com

    In terms of hotel growth, can you break down the growth in terms of investment and new hotels being built and again where are you seeing the most hotels going in?

    Alvaro Concha

    Colombia has 32 projects underway in the hotel sector, with some of them being hotels looking for investment to improve their current infrastructure and some looking for startup capital. We are growing at least 200% for the last four years. We are adding almost 7000 new rooms that will be added to the 15,000 actual rooms in the country. In terms of areas, it's all across the country and broken down by leisure or business. Bogata has a lot of business growth, with Medellín and Cali as well benefiting. The main cities that need more hotels for business in particular are Bogotá, Cali and Medellín.

    Investorideas.com

    And can you tell us what hotel chains are now entering the market and who is looking at coming in?

    Alvaro Concha

    Right now Marriott, the Radisson, Hilton, Holiday Inn, Hyatt and other lead chains are coming in.

    New properties include:

    · Bastion Luxury Hotel (Cartagena) -The Bastion Luxury Hotel, which opened in Cartagena under GHL Hotels, has 51 luxury bedrooms and is modeled after 16th century colonial era buildings, though mixed with modern art and architecture. Located in the heart of Cartagena's historic district, the Bastion Luxury Hotel is perfect for travelers looking to explore the city's sites.

    · Cali Marriott Hotel (Cali) - The Cali Marriott Hotel opened in February 2014 in Granada, the heart of Cali's financial and entertainment district. Ideally located with 170 hotel rooms and modern amenities, the hotel includes the Tanoshii Lounge, a bar integrated into the outdoor pool and terrace where visitors can enjoy music, food and beverages and a vibrant atmosphere.

    · Radisson Cartagena Ocean Pavillion Hotel (Cartagena) - A new luxury hotel located on the gorgeous La Boquilla Beach in Cartagena, Radisson Cartagena Ocean Pavillion Hotel offers 233 rooms and premium on-site amenities including an outdoor pool, restaurants and bars and a state-of-the-art fitness center. The property opened in February 2014, and makes exploring attractions such as the ancient walled city district and the Fortress of San Felipe de Barajas easy and convenient.

    · Hotel Movich Buro 26 (Bogota) -Bogota's Buro 26, which opened in April 2014, is the newest addition to the Movich Hotels. The 252 room hotel, adjoined to El Dorado International Airport, is convenient for all travelers seeking modern amenities, event space, fine dining, a trendy bar and lounge and top of the line gym and spa facilities.

    · W Bogota Hotel (Bogota) - Slated to open in September 2014, W Bogota Hotel is a 168 room property, including 33 suites and an Extreme Wow Suite, in the upscale Santa Barbara Business Center. With its convenient location, modern amenities and 818 square meters of dynamic function venues, the hotel will be an ideal place for both business and leisure travel.

    Investorideas.com

    Where do you still see the biggest need for new hotels, what cities and areas?

    Alvaro Concha

    In terms of business infrastructure, the main cities that need more hotels for business in particular are Bogotá, and Medellín. For example, next week the city is hosting Colombiamoda, Colombia's Fashion Week, one of the most important shows with over 1800 international buyers from 50 different nationalities.

    We are taking 35 companies from Canada to the event and the city is sold out for hotels. Cartagena is the major target to grow in terms of business and tourism. Cartagena needs investment in resorts and there are several projects being presented to potential investors.

    Investorideas.com

    On a related note to hotel growth, I watched a segment on CNN that talked about restaurant growth in Colombia - they looked at Bogata and Cali for new and exciting restaurants - scale up from casual dining - reflecting the new money in the country from visitors and locals. Is this something Pro export is working on?

    Alvaro Concha

    I don't have the numbers but what I can tell you is the restaurant industry is growing very fast. The last numbers I heard was that Bogotá now has over 600 different restaurants and you will find a varied international and local cuisine mix. I see one or two new restaurants in Medellín, Cartagena or Bogotá every time I go. It is part of the 200% growth in tourism we are seeing.

    Investorideas.com

    We have talked about it before, but for new readers, why is Colombia such a safe place for investment?

    Alvaro Concha

    According to the Central Bank in regards to FDI we had an 8% increase in 2013. We are considered one of the top 20 destinations in the world for foreign direct investment. According to the World Bank for doing business Colombia is third in the region. We are number one in the region to better protect investors and we are ranked 6th in the world in that index.

    We are ranked first in the region for skilled labor.

    Colombia is not only a safe country but it's also a very strong competitor when you think about investing in the region We are third largest economy in the region after Mexico and Brazil.

    We have the second largest Spanish speaking population in the world after Mexico.

    Our unemployment rate is the lowest in the past twenty years. We are now at 8.5% and the government is working seriously on improving that number.

    Our GDP growth last year was 4.3%

    This year, the first quarter is showing growth at 6.3 %, second only to China in the world. This is the fastest growth in Latin America.

    Investorideas.com

    How is Colombia set up for technology and IT for new companies looking at coming into the country?

    Alvaro Concha

    We have an established IT Ministry that is looking at how to improve our competiveness in this sector and we have a growing industry. You will find at least 2500 different export companies in the IT sector including mobile applications, software development, gaming and digital animation. That is where we are concentrating our efforts. Medellin wants to be the most innovative city in the world and was in fact named exactly that last year by Citi Bank.

    There are several Hubs but Medellín is one of the most promising and is looking at becoming the IT Hub in the country. This city is driven at looking after the IT sector.

    In terms of labor, the number of graduates in engineering fields is very much on the rise. There is also a training institute in Colombia where you can actually train your staff and the government will help. We have done it in the past for Canadian companies where trained employees are now working.

    We are also hosting an IT match-making event in New York next week with 70 companies from Colombia meeting companies from the US and Canada.

    Also in terms of the Pacific Alliance, which we are a member of, 74% of the high and medium technology products exported from Latin America are coming from the Pacific Alliance members

    Investorideas.com

    If you were to summarize some of the key successes of Proexport, what would you say are some of the most important?

    Alvaro Concha

    As Colombia's Trade Commissioner in Canada, for the past three years that I have been here we have diversified our portfolio not only in the investment side but also in trade. We thought and believed there were other sectors that needed to be invited to the party. Today we are seeing the pension funds investing in our country but also seeing other companies and other sectors looking at investing in a more precise way.

    In the trade side, we have taken full advantage of the Free Trade Agreement. We have over 140 new products that have been exported to Canada and over 350 new companies are selling in the Canadian market.

    Investorideas.com

    Thanks as always and let's hope you take the World Cup next time!

    About ALVARO CONCHA

    Alvaro Concha, Colombia's Trade Commissioner in Canada since 2011, is an experienced professional with over 15 years' experience in global business and market-development strategies. As head of the Canadian offices of Proexport Colombia - the country's investment, tourism and export promotion agency - Mr. Concha has worked tirelessly to strengthen Colombia's trade relationship with Canada. Mr. Concha's leadership has resulted in a significant increase in Colombian exports to Canada, the securing of a new roster of important Canadian investors in Colombia, and a surge in the number of Canadian tourists visiting Colombia.

    Before being appointed to Canada, Mr. Concha worked as Colombia's trade commissioner in Italy and headed the joint Guatemala, Honduras, and El Salvador office headquartered in Guatemala City. Throughout his career in Proexport Colombia, his goal has remained the same: to bring prosperity to all Colombians by bringing the best of Colombia to the rest of the world.

    Mr. Concha holds a Bachelor's Degree in Business Administration from EAFIT University in Medellin, Colombia, and an MBA from the EEN - Escuela Europea de Negocios in Madrid, Spain.

    About Proexport Colombia

    http://www.proexport.com.co/en

    Proexport provides business opportunities, clear information on requirements, strategies for expanding services and goods at an international level, participation in business fairs and assistance by experts for investors, exporters, and professionals that wish to come closer to their dreams.

    About Investorideas.com

    InvestorIdeas.com is a global news source and research resource covering leading sectors including social media, tech, biotech, defense, water, mining and energy and Latin America.

    Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

    Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

    Sign up for free news alerts at Investorideas.com

    http://www.investorideas.com/Resources/Newsletter.asp

    Become an Investorideas.com Member and access our online stock directories listing thousands of publicly traded stocks in leading sectors

    http://www.investorideas.com/membership/

    Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp

    BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

    Contact Investorideas.com 800 665 0411

    Jul 22 10:34 AM | Link | Comment!
  • Kareg Corporation Initiates Coverage On GenSpera (OTCQB:GNSZ) With A Speculative Buy Recommendation

    GenSpera, Inc. (OTCQB:GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces that Kareg Corporation's Director of Research, Sheldon S. Traube, has issued the following research report on the company.

    www.investorideas.com/CO/GNSZ/news/2014/...

    Jul 14 2:12 PM | Link | Comment!
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.